MCID: PTT006
MIFTS: 50

Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 11 58 28 53 14 71 75
Adenoma of the Pituitary Gland 11
Pituitary Gland Adenoma 16
Pituitary Neoplasms 71
Pituitary Adenomas 14
Adenoma, Pituitary 38

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 11 DOID:3829
MeSH 43 D010911
NCIt 49 C3329
SNOMED-CT 68 154621002
ICD10 via Orphanet 32 D35.2
UMLS via Orphanet 72 C0032000
Orphanet 58 ORPHA99408
UMLS 71 C0032000 C0032019

Summaries for Pituitary Adenoma

Disease Ontology: 11 A pituitary gland benign neoplasm that derives from glandular epithelial cells.

MalaCards based summary: Pituitary Adenoma, also known as adenoma of the pituitary gland, is related to functionless pituitary adenoma and thyroid carcinoma. An important gene associated with Pituitary Adenoma is MIR15A (MicroRNA 15a), and among its related pathways/superpathways are miRNA regulation of DNA damage response and Cell differentiation - expanded index. The drugs Hydrocortisone succinate and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and hypothalamus.

Wikipedia: 75 Pituitary adenomas are tumors that occur in the pituitary gland. Most pituitary tumors are benign,... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 912)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 32.4 MEG3 HOTAIR
2 thyroid carcinoma 31.0 MALAT1 HOTAIR H19
3 thyroid cancer, nonmedullary, 1 30.8 MEG3 MALAT1 HOTAIR H19
4 glioma 30.5 MIR15A MEG3 MALAT1 HOTAIR H19 CCAT2
5 osteogenic sarcoma 30.4 MEG3 MALAT1 HOTAIR H19 CCAT2
6 high grade glioma 30.3 MEG3 MALAT1 HOTAIR H19
7 lung cancer susceptibility 3 30.1 MIR15A MIR149 MEG3 MALAT1 HOTAIR H19
8 myeloma, multiple 30.0 MIR15A MEG3 MALAT1 HOTAIR H19
9 cervix carcinoma 30.0 MIR24-1 MIR15A MIR149
10 endocrine gland cancer 30.0 MIRLET7A1 MIR24-1 MIR223 MIR212 MIR15A MIR149
11 focal epilepsy 29.9 MIR212 MIR132 MIR128-1
12 cerebrovascular disease 29.9 MIR223 MIR212 MIR132 MEG3 HOTAIR
13 leukemia, chronic lymphocytic 29.9 MIR24-1 MIR223 MIR16-1 MIR15A MIR132
14 retinitis pigmentosa 11 29.9 MIR136 HOTAIR CCAT2
15 kidney cancer 29.9 MIR15A MEG3 MALAT1 HOTAIR H19
16 head and neck cancer 29.8 MIRLET7A1 MIR24-1 MIR15A MIR149
17 pre-eclampsia 29.7 MIR136 MALAT1 HOTAIR H19
18 bladder cancer 29.7 MIR26B MIR223 MEG3 MALAT1 HOTAIR H19
19 melanoma 29.6 MIR15A MIR149 MIR128-1 MEG3 MALAT1 HOTAIR
20 central nervous system cancer 29.6 MIRLET7A1 MIR7-1 MIR24-1 MIR223 MIR15A MIR149
21 glioblastoma 29.5 MIR24-1 MIR197 MIR149 MIR132 MIR128-1 MEG3
22 carbohydrate metabolic disorder 29.5 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR15A MIR132
23 prostate disease 29.3 MIRLET7A1 MIR24-1 MIR223 MIR15A MIR149 MEG3
24 gastrointestinal system disease 29.3 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR15A
25 nasopharyngeal carcinoma 29.2 MIR26B MIR223 MIR212 MIR197 MIR149 MIR132
26 parkinson disease, late-onset 29.2 MIR24-1 MIR223 MIR212 MIR132 MIR128-1 MALAT1
27 esophageal cancer 29.2 MIR24-1 MIR223 MIR197 MIR149 MEG3 MALAT1
28 prostate cancer 29.1 MIRLET7A1 MIR26B MIR223 MIR16-1 MIR15A MIR149
29 leukemia, acute myeloid 29.1 MIR7-1 MIR223 MIR212 MIR149 MIR128-1 MEG3
30 gastric cancer 29.1 MIR24-1 MIR223 MIR16-1 MIR15A MIR149 MEG3
31 pancreatic cancer 29.1 MIRLET7F1 MIR24-1 MIR223 MIR212 MIR16-1 MIR15A
32 reproductive system disease 29.1 MIRLET7A1 MIR7-1 MIR24-1 MIR223 MIR212 MIR16-1
33 malignant astrocytoma 29.1 MIRLET7A1 MIR7-1 MIR24-1 MIR223 MIR212 MIR15A
34 alzheimer disease, familial, 1 29.0 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR197
35 body mass index quantitative trait locus 11 29.0 MIRLET7F1 MIRLET7A1 MIR26B MIR223 MIR212 MIR149
36 renal cell carcinoma, nonpapillary 28.9 MIRLET7F1 MIR223 MIR212 MIR197 MIR15A MIR149
37 central nervous system disease 28.8 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR15A
38 hepatocellular carcinoma 28.1 MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223 MIR212
39 nervous system disease 27.9 MIRLET7F1 MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223
40 pituitary adenoma 1, multiple types 11.9
41 acth-secreting pituitary adenoma 11.8
42 gastrointestinal defects and immunodeficiency syndrome 1 11.8
43 pituitary adenoma 5, multiple types 11.8
44 pituitary adenoma 2, growth hormone-secreting 11.8
45 prolactinoma 11.7
46 pituitary adenoma 3, multiple types 11.7
47 functioning pituitary adenoma 11.7
48 growth hormone secreting pituitary adenoma 11.6
49 pituitary adenoma 4, acth-secreting 11.6
50 tsh producing pituitary tumor 11.5

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
6
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
7
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
Morphine Approved, Investigational Phase 4 57-27-2 5288826
13
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
14
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
15
Cefuroxime Approved Phase 4 55268-75-2 5479529
16
Cefdinir Approved Phase 4 91832-40-5 6915944
17
Cefazolin Approved Phase 4 25953-19-9 33255
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
21
Quinagolide Approved, Investigational Phase 4 87056-78-8
22
Cabergoline Approved Phase 4 81409-90-7 54746
23
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
24
Lactitol Approved, Investigational Phase 4 585-86-4 157355
25
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
26
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
30 Hydrocortisone 17-butyrate 21-propionate Phase 4
31 Pharmaceutical Solutions Phase 4
32 Antineoplastic Agents, Hormonal Phase 4
33 Gastrointestinal Agents Phase 4
34 HIV Protease Inhibitors Phase 4
35
protease inhibitors Phase 4
36 Antirheumatic Agents Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Anti-Inflammatory Agents, Non-Steroidal Phase 4
39 Analgesics, Opioid Phase 4
40 Narcotics Phase 4
41 Insulin, Globin Zinc Phase 4
42
Insulin Phase 4
43
Sitagliptin Phosphate Phase 4 654671-77-9
44 Dipeptidyl-Peptidase IV Inhibitors Phase 4
45 Incretins Phase 4
46 Folate Phase 4
47 Vitamin B9 Phase 4
48 Vitamin B Complex Phase 4
49 Anti-Bacterial Agents Phase 4
50 Antibiotics, Antitubercular Phase 4

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
5 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
6 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
7 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor;IV Placebo
8 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
9 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
10 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
11 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
12 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
13 Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas Terminated NCT00720902 Phase 4 growth hormone releasing hormone (GHRH) & arginine
14 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
15 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
16 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
17 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
18 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
19 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
20 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
21 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
22 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
23 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
24 Comparison Between Hemodynamic Effect of Bilateral Infraorbital Block Versus Intranasal Application of Bupivacaine in Patients Undergoing Transsphenoidal Pituitary Adenoma Resection.A Comparative Randomized Controlled Study Recruiting NCT05301634 Phase 3
25 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
26 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
27 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
28 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
29 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Terminated NCT02419664 Phase 3 Gallium-68 DOTATOC PET
30 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
31 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
32 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
33 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
34 Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
35 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Completed NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
36 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
37 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
38 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
39 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
40 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
41 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
42 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease Recruiting NCT04339751 Phase 2 Vorinostat
43 SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome Recruiting NCT05307328 Phase 2 SPI-62;Placebo
44 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab
45 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Active, not recruiting NCT03774446 Phase 2 Seliciclib
46 Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery Not yet recruiting NCT05005715 Phase 2 Dexmedetomidine;normal saline
47 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
48 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
49 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
50 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 28

Anatomical Context for Pituitary Adenoma

Organs/tissues related to Pituitary Adenoma:

MalaCards : Pituitary, Brain, Hypothalamus, Thyroid, Bone, Heart, Endothelial

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 13697)
# Title Authors PMID Year
1
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 62 46
17111382 2007
2
miR-15a and miR-16-1 down-regulation in pituitary adenomas. 62 46
15648093 2005
3
The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. 53 62
20335450 2010
4
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. 53 62
20233783 2010
5
Multiple endocrine neoplasia type 1-associated cystic pancreatic endocrine neoplasia and multifocal cholesterol granulomas. 53 62
20403035 2010
6
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 53 62
20111911 2010
7
Ghrelin's role on gastrointestinal tract cancer. 53 62
19328680 2010
8
Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? 53 62
20464704 2010
9
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 53 62
20106827 2010
10
Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. 53 62
19472104 2010
11
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 53 62
20150876 2010
12
[Rol of pituitary tumour-transforming gene (PTTG) in the pituitary adenomas]. 53 62
20172484 2010
13
Acromegaly pathogenesis and treatment. 53 62
19884662 2009
14
[Difficulties in the diagnosis of ACTH-dependent Cushing's syndrome in a patient after left adrenalectomy and treated with glucocorticoids]. 53 62
20041367 2009
15
No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. 53 62
19919817 2009
16
Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. 53 62
19684062 2009
17
The epidemiology and genetics of pituitary adenomas. 53 62
19945022 2009
18
Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. 53 62
20045804 2009
19
Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. 53 62
19443539 2009
20
[AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature]. 53 62
19883897 2009
21
[Outcome of somatostatin analogue treatment in acromegaly]. 53 62
19617182 2009
22
Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. 53 62
19477929 2009
23
The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. 53 62
19366855 2009
24
Familial pituitary adenomas. 53 62
19522822 2009
25
Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. 53 62
19356755 2009
26
Somatostatin-dopamine ligands in the treatment of pituitary adenomas. 53 62
18651224 2009
27
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. 53 62
19141603 2009
28
Genetic, molecular and clinical features of familial isolated pituitary adenomas. 53 62
19407507 2009
29
Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro. 53 62
19300395 2009
30
Atypical clinical manifestations of multiple endocrine neoplasia type 1 syndrome. 53 62
19514648 2009
31
GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. 53 62
19236640 2009
32
Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. 53 62
19136928 2009
33
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. 53 62
19223528 2009
34
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. 53 62
19347192 2009
35
Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone. 53 62
18991502 2009
36
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 53 62
18840925 2009
37
Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism. 53 62
19293545 2009
38
Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. 53 62
19153518 2009
39
Pituitary adenoma stem cells. 53 62
19582428 2009
40
[Familial pituitary adenomas]. 53 62
18990538 2009
41
Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. 53 62
19188737 2009
42
Future treatment strategies of aggressive pituitary tumors. 53 62
19003539 2009
43
Management of aggressive pituitary adenomas: current treatment strategies. 53 62
19003540 2009
44
Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. 53 62
18787049 2008
45
The expression of ghrelin in somatotroph and other types of pituitary adenomas. 53 62
19112387 2008
46
p21(Cip1) restrains pituitary tumor growth. 53 62
18981426 2008
47
Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. 53 62
19169048 2008
48
Update on the treatment of pituitary adenomas: familial and genetic considerations. 53 62
19170361 2008
49
Large genomic deletions in AIP in pituitary adenoma predisposition. 53 62
18628514 2008
50
Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. 53 62
18410548 2008

Variations for Pituitary Adenoma

Copy number variations for Pituitary Adenoma from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 MIRLET7F1 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
2 RISC complex GO:0016442 9.81 H19 MEG3 MIR128-1 MIR132 MIR136 MIR149
3 extracellular vesicle GO:1903561 9.35 MIRLET7A1 MIR26B MIR24-1 MIR16-1 MIR15A

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.84 MIR24-1 MIR212 MIR149 MIR128-1
2 negative regulation of inflammatory response GO:0050728 9.8 MIR223 MIR16-1 MIR15A MIR149
3 miRNA-mediated gene silencing GO:0035195 9.77 MIRLET7F1 MIRLET7A1 MIR7-1 MIR26B MIR24-1 MIR223
4 negative regulation of angiogenesis GO:0016525 9.76 MIR24-1 MIR212 MIR16-1 MIR15A
5 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.65 MIR223 MIR149 MIR132
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.61 MIR24-1 MIR212 MIR132
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.58 MIR16-1 MIR15A MIR149
8 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR16-1 MIR15A
9 negative regulation of nitric-oxide synthase activity GO:0051001 9.55 MIR212 MIR132
10 negative regulation of peptidyl-cysteine S-nitrosylation GO:1902083 9.52 MIR212 MIR132
11 negative regulation of macrophage migration GO:1905522 9.51 MIR24-1 MIR128-1
12 positive regulation of endothelial cell apoptotic process GO:2000353 9.5 MIR24-1 MIR15A MIR132
13 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.5 MIRLET7A1 MIR24-1 MIR212 MIR16-1 MIR15A MIR132
14 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.46 MIR149 MIR15A MIR16-1 MIR24-1
15 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.37 MIR16-1 MIR149
16 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.26 MIR16-1 MIR15A

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR24-1 MIR223 MIR212 MIR16-1 MIR15A MIR128-1
2 mRNA base-pairing translational repressor activity GO:1903231 9.4 MIRLET7F1 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212

Sources for Pituitary Adenoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....